Kariem Ezzat

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9185463/publications.pdf Version: 2024-02-01



KADIEM F77AT

#	Article	IF	CITATIONS
1	Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nature Medicine, 2015, 21, 270-275.	15.2	263
2	Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Research, 2011, 39, 3972-3987.	6.5	262
3	PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Research, 2011, 39, 5284-5298.	6.5	199
4	Peptides for nucleic acid delivery. Advanced Drug Delivery Reviews, 2016, 106, 172-182.	6.6	174
5	The viral protein corona directs viral pathogenesis and amyloid aggregation. Nature Communications, 2019, 10, 2331.	5.8	160
6	Scavenger receptorâ€mediated uptake of cellâ€penetrating peptide nanocomplexes with oligonucleotides. FASEB Journal, 2012, 26, 1172-1180.	0.2	127
7	C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia. Brain, 2017, 140, 887-897.	3.7	126
8	Delivery of nucleic acids with a stearylated (RxR)4 peptide using a non-covalent co-incubation strategy. Journal of Controlled Release, 2010, 141, 42-51.	4.8	113
9	A Peptide-based Vector for Efficient Gene Transfer In Vitro and In Vivo. Molecular Therapy, 2011, 19, 1457-1467.	3.7	94
10	PepFect14 Peptide Vector for Efficient Gene Delivery in Cell Cultures. Molecular Pharmaceutics, 2013, 10, 199-210.	2.3	83
11	Self-Assembly into Nanoparticles Is Essential for Receptor Mediated Uptake of Therapeutic Antisense Oligonucleotides. Nano Letters, 2015, 15, 4364-4373.	4.5	80
12	High cerebrospinal amyloid-β 42 is associated with normal cognition in individuals with brain amyloidosis. EClinicalMedicine, 2021, 38, 100988.	3.2	69
13	Solid formulation of cell-penetrating peptide nanocomplexes with siRNA and their stability in simulated gastric conditions. Journal of Controlled Release, 2012, 162, 1-8.	4.8	51
14	Synthetic SiRNA Delivery: Progress and Prospects. Methods in Molecular Biology, 2016, 1364, 291-310.	0.4	39
15	A convergent uptake route for peptide- and polymer-based nucleotide delivery systems. Journal of Controlled Release, 2015, 206, 58-66.	4.8	35
16	Soluble Amyloid-β Consumption in Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 82, 1403-1415.	1.2	31
17	Peptide-Based Matrices as Drug Delivery Vehicles. Current Pharmaceutical Design, 2010, 16, 1167-1178.	0.9	27
18	Role of autophagy in cell-penetrating peptide transfection model. Scientific Reports, 2017, 7, 12635.	1.6	23

KARIEM EZZAT

#	Article	IF	CITATIONS
19	Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP). Frontiers in Aging Neuroscience, 2020, 12, 553635.	1.7	22
20	Disentangling the Amyloid Pathways: A Mechanistic Approach to Etiology. Frontiers in Neuroscience, 2020, 14, 256.	1.4	21
21	The role of endocytosis in the uptake and intracellular trafficking of PepFect14–nucleic acid nanocomplexes via class A scavenger receptors. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 3205-3216.	1.4	17
22	Novel peptide-dendrimer/lipid/oligonucleotide ternary complexes for efficient cellular uptake and improved splice-switching activity. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 132, 29-40.	2.0	17
23	Proteins Do Not Replicate, They Precipitate: Phase Transition and Loss of Function Toxicity in Amyloid Pathologies. Biology, 2022, 11, 535.	1.3	14
24	Peptide Nanoparticles for Oligonucleotide Delivery. Progress in Molecular Biology and Translational Science, 2011, 104, 397-426.	0.9	13
25	Low soluble amyloid- \hat{l}^2 42 is associated with smaller brain volume in Parkinson's disease. Parkinsonism and Related Disorders, 2021, 92, 15-21.	1.1	8
26	Novel Orthogonally Hydrocarbon-Modified Cell-Penetrating Peptide Nanoparticles Mediate Efficient Delivery of Splice-Switching Antisense Oligonucleotides In Vitro and In Vivo. Biomedicines, 2021, 9, 1046.	1.4	6
27	Degradation of pristine and oxidized single wall carbon nanotubes by CYP3A4. Biochemical and Biophysical Research Communications, 2019, 515, 487-492.	1.0	4
28	Does the Antiâ€Tau Strategy in Progressive Supranuclear Palsy Need to Be Reconsidered? Yes. Movement Disorders Clinical Practice, 2021, 8, 1034-1037.	0.8	2
29	Extracellular amyloid deposition in sporadic inclusion body myositis: Further insights. Muscle and Nerve, 2021, 64, 517-519.	1.0	Ο